Disease · MONDO_0005230
Comparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 15 of 15
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Trimethoprim-sulfamethoxazole vs Placebo: Relative Efficacy | 62 of 73 | 60 of 73 | 146 | NCT00676130 | Trial comparisons |
| Trimethoprim-sulfamethoxazole vs Placebo: Progression to Abscess | 5 of 73 | 5 of 73 | 146 | NCT00676130 | Trial comparisons |
| Trimethoprim-sulfamethoxazole vs Placebo: serious adverse events | 0 of 73 | 1 of 73 | 146 | NCT00676130 | Trial comparisons |
| Tedizolid Phosphate vs Antibiotic Comparator Drug: Number of Participants With Investigator's Assessment Indicating Clinical Success at Test of Cure (TOC) Visit (Intent to Treat Analysis Set) | 88 of 91 | 27 of 29 | 120 | NCT02276482 | Trial comparisons |
| Tedizolid Phosphate vs Antibiotic Comparator Drug: Number of Participants With Investigator's Assessment Indicating Clinical Success at End of Therapy (EOT) Visit (Intent to Treat Analysis Set) | 88 of 91 | 28 of 29 | 120 | NCT02276482 | Trial comparisons |
| Tedizolid Phosphate vs Antibiotic Comparator Drug: Number of Participants With Early Clinical Responses Measured by Lesion Reduction | 84 of 91 | 28 of 29 | 120 | NCT02276482 | Trial comparisons |
| Tedizolid Phosphate vs Antibiotic Comparator Drug: Number of Participants With Adverse Events on Tedizolid Phosphate and Comparator Drugs | 13 of 91 | 3 of 29 | 120 | NCT02276482 | Trial comparisons |
| Tedizolid Phosphate vs Antibiotic Comparator Drug: deaths from any cause | 0 of 91 | 0 of 29 | 120 | NCT02276482 | Trial comparisons |
| Tedizolid Phosphate vs Antibiotic Comparator Drug: serious adverse events | 1 of 91 | 0 of 29 | 120 | NCT02276482 | Trial comparisons |
Tedizolid Phosphate vs Antibiotic Comparator Drug: Number of Participants With Investigator's Assessment Indicating Clinical Success at EOT Visit (Clinically Evaluable-End of Therapy [CE-EOT] Analysis Set) | 87 of 87 | 27 of 27 | 114 | NCT02276482 | Trial comparisons |
Tedizolid Phosphate vs Antibiotic Comparator Drug: Number of Participants With Investigator's Assessment Indicating Clinical Success at TOC Visit (Clinically Evaluable-Test of Cure [CE-TOC] Analysis Set) | 87 of 87 | 26 of 27 | 114 | NCT02276482 | Trial comparisons |
| Buffered Lidocaine vs Nonbuffered Lidocaine: deaths from any cause | 0 of 45 | 0 of 43 | 88 | NCT01981772 | Trial comparisons |
| Buffered Lidocaine vs Nonbuffered Lidocaine: serious adverse events | 0 of 45 | 0 of 43 | 88 | NCT01981772 | Trial comparisons |
| Prednisone vs Placebo: deaths from any cause | 0 of 20 | 0 of 20 | 40 | NCT01671423 | Trial comparisons |
| Prednisone vs Placebo: serious adverse events | 0 of 20 | 0 of 20 | 40 | NCT01671423 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005230/comparisons